Table 2. Characteristics of 8 cases with clinical progression to CDC B or C during follow-up.
| Sex | Age (years) | Mode of infection with HIV | Baseline CD4+ T cell count (cells/μl) | Baseline viral load (copies/mL) | Time to ART (days) | ART inter-ruption | Progression to CDC stadium B or C and type of manifestation | Time to clinical progression (days) | On ART at the time of clinical progression | CD4+ T cell count (cells/μl) at the time of clinical progression | Viral load (copies/mL) at the time of clinical progression |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ART WITHIN 3 MONTHS (A) | |||||||||||
| male | 37 | homosexual | 696 | 4571 | 9 | no | C (Kaposi sarcoma) | 1715 | yes | unknown | unknown |
| NO ART WITHIN 3 MONTHS (B) | |||||||||||
| male | 57 | heterosexual | 417 | 95499 | 1837 | no | B (oropharyngeal candidiasis) | 1697 | no | 240 | 60256 |
| male | 32 | homosexual | 356 | 74131 | 167 | no | B (oropharyngeal candidiasis) | 1294 | yes | 959 | 19 |
| male | 38 | heterosexual | 452 | 630957 | 388 | no | B (constitutional symptoms) | 307 | no | 473 | 281838 |
| male | 40 | homosexual | 604 | 58884 | no ART | no | B (herpes zoster) | 899 | no | 1067 | 19498 |
| male | 40 | homosexual | 414 | 2754229 | 275 | yes | C (DLBCL) | 512 | yes | 326 | 49 |
| male | 30 | IVDU | 205 | 977237 | 1541 | no | B (herpes zoster) | 1327 | yes | 178 | 19 |
| male | 48 | IVDU | 129 | 758578 | 328 | yes | B (ITP) | 303 | no | 126 | 346736 |
ART = antiretroviral therapy; HIV = human immunodeficiency virus; IVDU = intravenous drug use; PI = protease inhibitor, NNRTI = non nucleoside reverse transcriptase inhibitor; CDC = Centers for Disease Control and Prevention; DLBCL = diffuse large cell B cell lymphoma; ITP = idiopathic thrombytopenic purpura.